Insulet DCF valuation and fair value (PODD)
Review Insulet's current market price, analyst target and financial fundamentals before building a discounted cash flow valuation.
Key company data
- Latest recorded price: $142.64 on 2026-10-20
- Market capitalization: $9.85B
- Price-to-earnings ratio: 26.58
- Analyst target price: $167.17
- Sector: Health Care Equipment
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Data last updated: